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Abstract
This review details and discusses the technological quality requirements to ensure the desired quality for stereotac-
tic radiotherapy using photon external beam radiotherapy as defined by the DEGRO Working Group Radiosurgery
and Stereotactic Radiotherapy and the DGMP Working Group for Physics and Technology in Stereotactic Radiother-
apy. The covered aspects of this review are 1) imaging for target volume definition, 2) patient positioning and target
volume localization, 3) motion management, 4) collimation of the irradiation and beam directions, 5) dose calcula-
tion, 6) treatment unit accuracy, and 7) dedicated quality assurance measures. For each part, an expert review for
current state-of-the-art techniques and their particular technological quality requirement to reach the necessary ac-
curacy for stereotactic radiotherapy divided into intracranial stereotactic radiosurgery in one single fraction (SRS),
intracranial fractionated stereotactic radiotherapy (FSRT), and extracranial stereotactic body radiotherapy (SBRT) is
presented. All recommendations and suggestions for all mentioned aspects of stereotactic radiotherapy are formu-
lated and related uncertainties and potential sources of error discussed. Additionally, further research and development
needs in terms of insufficient data and unsolved problems for stereotactic radiotherapy are identified, which will serve as
The authors D. Schmitt and O. Blanck contributed equally to the
manuscript.
Electronic supplementary material The online version of this
article (https://doi.org/10.1007/s00066-020-01583-2) contains
supplementary material, which is available to authorized users.
 Daniela Schmitt, PhD
Daniela.Schmitt@med.uni-heidelberg.de
1 Klinik für Radioonkologie und Strahlentherapie, National
Center for Radiation Research in Oncology (NCRO),
Heidelberger Institut für Radioonkologie (HIRO),
Universitätsklinikum Heidelberg, Heidelberg, Germany
2 Klinik für Strahlentherapie, Universitätsklinikum
Schleswig-Holstein, Kiel, Germany
3 Klinik für Strahlentherapie und Radioonkologie,
Universitätsklinikum Hamburg-Eppendorf, Hamburg,
Germany
4 Abteilung für Medizinische Strahlenphysik
und Universitätsklinik für Radio-Onkologie,
Inselspital—Universitätsspital Bern, Universität Bern, Bern,
Switzerland
5 Universitätsklinik für Strahlentherapie, Universitätsklinikum
Magdeburg, Magdeburg, Germany
6 Klinik für Strahlentherapie und Radioonkologie,
Universitätsmedizin Mannheim, Universität Heidelberg,
Mannheim, Germany
7 Klinik für Strahlentherapie und Onkologie,
Universitätsklinikum Frankfurt, Frankfurt am Main, Germany
8 Institut für Computational Neuroscience,
Universitätsklinikum Hamburg-Eppendorf, Hamburg,
Germany
9 Klinik für Strahlentherapie, Universitätsmedizin Rostock,
Rostock, Germany
10 Klinik für Radioonkologie, CyberKnife- und Strahlentherapie,
Universitätsklinikum Köln, Cologne, Germany
11 Klinik für Strahlentherapie—Radioonkologie,
Universitätsklinikum Münster, Münster, Germany
K
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
4
7
3
3
1
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
422 Strahlenther Onkol (2020) 196:421–443
a basis for the future assignments of the DGMP Working Group for Physics and Technology in Stereotactic Radiotherapy.
The review was group peer-reviewed, and consensus was obtained through multiple working group meetings.
Keywords Radiosurgery · Recommendations · Technique · SRS · FSRT · SBRT
Abbreviations
AAA Anisotropic analytical algorithm
AAPM American association of physicists in medicine
ACROP Advisory committee on radiation oncology prac-
tice of the ESTRO
AVM Arteriovenous malformation
CBCT Cone-beam computed tomography
COMP Canadian organization of medical physicists
CT Computed tomography
CTV Clinical target volume
DEGRO Deutsche Gesellschaft für Radioonkologie (Ger-
man Society for Radiation Oncology)
DGMP Deutsche Gesellschaft für Medzinische Physik
(German Society for Medical Physics)
DIN Deutsches Institut für Normung (German Institute
for Standardization)
DSA Digital subtraction angiogram
ESTRO European Society for Radiotherapy and Oncology
FLAIR Fluid-attenuated inversion recoveryMRI sequence
FSRT Intracranial fractionated stereotactic radiotherapy
GTV Gross tumor volume
IAEA International Atomic Energy Agency
ICRU International Commission on Radiation Units and
Measurements
IGRT Image-guided radiotherapy
IMAT Intensity-modulated arc therapy
IMRT Intensity-modulated radiotherapy
ITV Internal target volume
MidV Mid-ventilation
MLC Multileaf collimator
MRI Magnetic resonance imaging
OAR Organ at risk
PET Positron-emission tomography
PSMA Prostate-specific membrane antigen
PTV Planning target volume
RSS Radiosurgery Society
SBRT Extracranial stereotactic body radiotherapy
SRS Intracranial stereotactic radiosurgery
Introduction
The Working Group Radiosurgery and Stereotactic Radio-
therapy of the German Society for Radiation Oncology
(DEGRO) and the Working Group for Physics and Tech-
nology in Stereotactic Radiotherapy of the German Society
for Medical Physics (DGMP) jointly published a consen-
sus statement for the definition of and quality requirements
for intracranial stereotactic radiosurgery in one single frac-
tion (SRS), intracranial fractionated stereotactic radiother-
apy (FSRT), and extracranial stereotactic body radiotherapy
(SBRT) [1], further jointly denoted as stereotactic radiother-
apy if not specifically addressed.
Stereotactic radiotherapy is defined as a method of per-
cutaneous external beam radiotherapy, in which a clearly
defined target volume is treated accurately with a high radi-
ation dose in up to 12 fractions with locally curative intent.
Importantly in this context, a risk-adapted adjustment of the
fractionation and the total dose based on the volume and lo-
cation of the target is essential. Additionally, technological
quality requirements in terms of 1) imaging for target vol-
ume and organs-at-risk definition, 2) patient positioning and
target volume localization, 3) management of periodic and
non-periodic target motion, 4) collimation of the irradiation
and beam direction, 5) dose calculation, 6) geometric and
dosimetric treatment unit accuracy, and 7) dedicated quality
assurance measures were presented in the DEGRO/DGMP
consensus statement. Furthermore, process quality require-
ments in terms of standard operating procedures, interdis-
ciplinary discussion, training, experience, documentation,
and reporting for stereotactic radiotherapy were defined.
The present expert review provides the background and
details for each of the technological quality requirements
for stereotactic radiotherapy as described in the consen-
sus statement [1], taking into account the current state-of-
the-art clinical practice. Furthermore, this review discusses
and explores further needs for research and development to
overcome unsolved problems.
Expert review
For the investigation of existing methods, results and open
questions for each technological quality requirement for
stereotactic radiotherapy, an expert review was performed
and summarized. For the specific technological quality re-
quirement “treatment unit accuracy”, a dedicated distributed
literature search in PubMed/Medline for the past 6 years
(2013–2018) for the keyword combinations (sbrt OR sabr
OR srs OR srt OR stereotaxy OR (stereotactic AND (radio-
therapy OR radiosurgery))) AND either a) end-to-end, b)
E2E, c) (mechanical OR geometric) accuracy, d) dosimet-
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ric accuracy, e) quality assurance, f) accuracy guidelines,
g) dosimetry audit, or h) credentialing was performed.
In order to avoid bias, a group peer review with 15 re-
viewers (see acknowledgments) was performed to reach ini-
tial agreement on this expert review. Additionally, this re-
view was openly discussed at two working group meetings
before and after the group peer review, each with more than
100 participants, and consensus was obtained for remaining
critical questions via ballots.
Technological quality requirements for
stereotactic radiotherapy
The following technology quality requirements are spec-
ified additionally and/or are substantiated specifically for
stereotactic radiotherapy and do not render other established
guidelines for general radiation protection and radiotherapy
obsolete. In the following sections, we first present the spe-
cific technological quality requirements as defined by the
DEGRO/DGMP consensus statement [1] and then discuss
the current state-of-the-art and its limitations based on the
literature review.
Imaging for target volume definition
Requirement: The target volume and all organs-at-risk are
defined using organ-specific imaging modalities and stan-
dardized imaging protocols dedicated for stereotactic radio-
therapy procedures. The use of secondary imaging requires
accurate registration with the thin-slice planning computed
tomography (CT).
The volume definition of intracranial and extracranial
stereotactic targets and the definition of organs at risk
(OAR) require the acquisition of organ- and indication-
specific planning image data. In general, high-quality, thin-
slice (organ and lesion volume-specific with 1mm in-
tracranial and 2mm extracranial slice thickness [2]) non-
contrast enhanced CT with maximum possible in-plane
resolution (organ and lesion volume-specific with 1mm
intracranial and 1.5mm extracranial pixel edge length) is
the primary planning imaging modality for target volume
and OAR definition and dose calculation purposes. The
selection of scan length should not only consider target
structures and radiation-sensitive structures that might be
affected by the treatment or be necessary for dose docu-
mentation, e.g., the whole lung for lung treatments, but also
consider the treatment technique, e.g., an extension of the
target region of 15cm in superior and inferior directions for
non-coplanar SBRT [2]. If unambiguous target definition is
not possible on primary planning imaging data, secondary
image data must be acquired and registered to the primary
data to achieve maximum confidence in delineating the
gross tumor/target volume (GTV) and to minimize proce-
dural safety margins [3]. In the following section, general
aspects related to the registration accuracy are summarized,
followed by organ-specific paragraphs to review secondary
planning imaging modalities.
Primary and secondary planning image data should
be acquired with the patient in treatment position using
well-defined, standardized imaging protocols dedicated for
stereotactic radiotherapy procedures. Planning data from
external imaging devices are a major source of displace-
ment in the patient anatomy (deviating immobilization
devices, tabletop, etc.), non-standardized image quality,
and undocumented artifacts. Poor image contrast and im-
age artifacts considerably hamper the clinician’s capability
to perform and verify image registration, but also influence
the accuracy of image registration and, if applicable, the
auto-detection of implanted fiducial markers [4]. Secondary
magnetic resonance imaging (MRI) data are preferably ac-
quired in the axial plane and on the same day as the primary
planning CT, and the acquisition of dedicated simulation
MRI for radiotherapy planning should be considered [5].
Hier steht eine Anzeige.
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Each MRI sequence should be corrected for geometric
distortions in the intrinsic imaging processing method of
the MRI scanner (with a 3D approach if possible). The
receiver bandwidth should be set to the highest value pos-
sible that still delivers an acceptable signal-to-noise ratio,
as the accuracy of the MRI images (especially in tissue
transition zones) could be a concern for contouring and for
simulation [3, 5].
Overall, accurate image registration depends on image
acquisition settings, sufficient spatial resolution, and image
quality. It also relies on the selected registration algorithms
and user-defined parameters (e.g., region of interest, soft
tissue versus bone registration, landmarks, registration cost
function, etc.). Rigid registration algorithms are currently
considered the standard approach in radiotherapy practice
[4, 6]. In areas of low contrast in the primary planning
CT (e.g., in the liver), fiducial markers implanted prior to
treatment planning imaging could improve the registration
accuracy. However, rigid registration algorithms are chal-
lenged by non-linear deformations mainly associated with
variation of organ position, shape, and volume between the
primary and secondary image acquisition. Some non-lin-
ear deformations can be eliminated by the use of individual
sub-volumes to optimize the registration process or through
different importance factors to selected anatomical regions.
In general, deformable image registration may further im-
prove rigid registration results and minimize subsequent
safety margins.
Regardless of the method, image registration requires
careful validation before clinical implementation, and case-
by-case evaluation due to large variation in the complex-
ity and robustness of the registration approaches is strongly
recommended [4, 6–8]. Furthermore, the use of automated
registration methods or auto-detection algorithms for im-
planted fiducials requires the evaluation of the system’s
performance for various image acquisition settings (e.g.,
to identify image quality limits where the algorithm fails)
to establish appropriate institutional imaging registration
protocols [4, 6].
Intracranial
Since lesions or OAR in the brain are often not visible
on non-contrast-enhanced CT, MRI, or in case the patient
cannot undergo MRI, contrast-enhanced CT is the stan-
dard imaging modality to define target volumes and OAR
for intracranial indications. MRI planning images should
be generally acquired with a maximum slice thickness of
1–1.5mm and minimum field strength of 1.5T [3, 9–11].
Contrast-enhanced T1-weighted imaging is commonly used
for brain metastases or uveal melanomas. Of note for brain
metastases: significant target volume changes may occur
if the time between planning imaging and treatment de-
livery exceeds 1 week or if new decongestant medication
is administered after planning imaging [12, 13]. For tu-
mor resection cavities, additional pre- and direct postop-
erative (48h after surgery [14]) contrast-enhanced T1-
weighted sequences are desirable. For non-enhancing brain
tumors, T2-weighted and/or fluid-attenuated inversion re-
covery (FLAIR) sequences or positron-emission tomogra-
phy (PET) are mainly used for target definition. However,
specific circumstances of a wide range of benign and malig-
nant brain tumors will require additional specific sequences
or the use of PET.
Target volumes of vascular disorders in the brain such
as arteriovenous malformations (AVM) are defined using
stereoscopic 2D digital subtraction angiograms (DSA) in
combination with registered CT angiograms and/or MRI
angiograms. Volumetric contrast-enhanced thin-slice (max.
1–1.5mm) MRI and/or high-resolution contrast-enhanced
CT scans and/or cone-beam computed tomography (CBCT)
angiography are considered alternative imaging modalities
[3, 10, 15], but typically lack detailed hemodynamic infor-
mation compared to DSA imaging.
Spine/bone
Target volumes in the spine or in extracranial bones and
OAR are commonly defined using high-resolution CT
and/or MRI and/or PET or in case of spinal AVM, using
DSA. MRI and/or PET may allow for better definition of
the tumor lesion within the bone and potential epidural
disease extension whereas T2-weighted MRI may provide
the highest resolution. Volumetric T1-/T2-weighted MRI
sequences are generally rigidly registered locally to a thin-
slice planning CT (1–2mm slice thickness depending on
target volume and location). The delineation of the spinal
cord can be performed using either T2-weighted MRI or
a CT myelogram in cases where the patient is unable to
undergo MRI or if the spinal cord is not clearly visible on
MRI, e.g., due to significant metal artefacts [3, 16–18].
Lung/mediastinum
CT is the standard imaging modality for target definition
of lung tumors and for OAR contouring. The planning CT
(2mm slice thickness) for lung tumors should cover the
entire ipsi- and contralateral lung. To improve target volume
definition, functional imaging such as FDG-PET or intra-
venous contrast-enhanced CT data (e.g., for central tumors)
may be used, desirably time-resolved [19–21]. In addition
to GTV definition, the planning image data is also acquired
to assess patient-specific target motion and deformation as
well as to evaluate correlation consistency of tumor mo-
tion in relationship to any internal or external markers prior
to treatment. The CT acquisition technique (e.g., 4D-CT,
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prospectively gated multiphase CT, breath-hold CT) has to
be chosen according to the motion management strategy ap-
plied during treatment delivery, as defined in the “Motion
management” section below [3, 16, 17, 19–23].
Liver/abdomen
Planning CT imaging (2mm slice thickness) for abdom-
inal tumors is identical to lung tumors, though it should
be noted that organ motion in the abdomen can be signifi-
cantly larger than in the lung [24] and be non-periodic due,
e.g., to digestion [25]. However, non-contrast-enhanced CT
is in the vast majority cases not sufficient for GTV defini-
tion of abdominal tumors (e.g., for liver or pancreatic tu-
mors) [26, 27] and for OAR contouring (e.g., for vessels).
Secondary high-contrast image data are acquired through
breath-hold or time-resolved (4D) contrast-enhanced CT
[28, 29] and/or through breath-hold MRI using T2- and
multiple T1-weighted sequences dynamically during and/or
0–20min after injection of intravenous contrast agents. If
applicable, the MRI breath-hold phase should coincide with
the breathing phase of primary planning CT used for con-
touring. However, the CT/MRI may underestimate the ab-
dominal tumor extensions compared to the pathological
specimens [30, 31]. Additionally, (4D)-PET-CT imaging
may, depending on the tumor histology, improve target vol-
ume delineation in contrast to the surrounding edema and
in the presence of organ motion/deformation [3, 16, 17,
25–27].
Prostate
Target and OAR delineation for primary prostate cancer
for stereotactic radiotherapy is performed using high-res-
olution (1.5mm slice thickness) CT and MRI. The scan
length should ideally be extended by 15cm superiorly and
inferiorly beyond the prostate to cover the testicles, blad-
der, sigma, rectum, and lower small bowel [2, 32]. Com-
bined planning CT/MRI data reduce delineation variability
compared to CT data alone. Additionally, prostate defini-
tion based on standard T1/T2 MRT sequences results in
a smaller CTV (e.g., in the area of prostate apex and ante-
rior rectal wall) and thus provides more effective sparing of
the rectum and neurovascular bundle and additionally en-
ables delineation and potentially sparing the urethra of high
doses [3, 32–34]. Additionally, Prostate-specific membrane
antigen(PSMA)-PET-CT could increase the definition ac-
curacy of the intra-prostatic lesion if a simultaneous boost
for SBRT is considered [35].
Discussion
Generally, non-contrast enhanced CT is the primary plan-
ning imaging modality, as the use of contrast agents or
other imaging modalities could lead to inaccuracies in dose
calculation and image registration during treatment. Many
indications for stereotactic radiotherapy require high-reso-
lution MRI or contrast-enhanced CT for accurate target and
OAR delineation, for which in most clinical scenarios ac-
curate registration to the primary planning CT is required
[3, 6, 9–11, 16–27]. However, quality requirements (e.g.,
for optimal contrast, artefact reduction, slice thickness, and
registration) and quality assurance (e.g., methods, tools, and
interval) of planning imaging devices are largely lacking for
stereotactic radiotherapy. Furthermore, the detailed docu-
mentation in published manuscripts of important imaging
parameters (e.g., imaging and registration modalities, pro-
tocols and processing methods, and recommended window
settings) or even the methods for contouring of the OARs
(e.g., imaging modalities and average CT vs. multiple phase
CT for moving organs) are hardly found. This makes the
crucial target and OAR delineation process especially diffi-
cult to compare among institutions. Additionally, the time
delay between planning imaging and treatment plays an im-
portant role for brain metastases [12, 13]; yet, for other in-
dications, it is largely unexplored, and in general this factor
is largely unreported in the literature. Lastly, consensus for
follow-up imaging including corresponding quality require-
ments (e.g., registration to the treatment plan) and methods
for differentiating tumor recurrence vs. radiation reactions
is largely lacking, despite already existing studies in the
literature [36–38].
Patient positioning and target volume localization
Requirement: Daily in-room image-guidance and online
correction of target position errors using on-board CT, sup-
plementary in-room CT or stereoscopic X-ray is required.
 For SRS, an invasive fixation using a stereotactic head
frame can be used alternatively to image guidance.
 For SRS and FSRT, non-invasive fixation of the patient’s
head is combined with image guidance.
 For SBRT, image-guidance of the target itself (or a sur-
rogate structure highly correlated with the target) is re-
quired. The optimal image-guidance strategy is depen-
dent on the tumor site and location and needs to consider
the following principles:
– in cases of target motion relative to the bony anatomy,
image-guidance requires volumetric imaging with or
without implanted fiducial markers or electromagnetic
transponders or requires stereoscopic X-ray imaging
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of the target itself or of implanted fiducial markers as
target surrogate.
– in cases at risk of serial organs-at-risk motion into ar-
eas of critical radiation doses, volumetric image guid-
ance is recommended.
For treatment delivery, the patient has to be immobilized
and positioned identically to the primary treatment planning
imaging. The target volume itself or appropriate surrogates,
if the target is not visible on setup verification imaging (e.g.,
bony anatomy for brain or spinal lesions [39] or implanted
fiducial markers for abdominal or prostate lesions [3, 16,
17, 25, 26, 40, 41]) have to be localized in the treatment
room directly before treatment. Because of known data on
possible intrafractional target motion [42–45], we strongly
recommend to define an institutional maximum time delay
between setup verification image acquisition and start of
treatment for all treatment sites, with a time delay as short as
possible. To meet the accuracy requirements for stereotactic
radiotherapy, this time delay should not exceed 5min for
most treatment sites [42–45].
For patient positioning and target volume localization,
there currently exist no state-of-the-art setup devices be-
sides invasive stereotactic head frames that are able to guar-
antee the needed positioning accuracy for stereotactic radio-
therapy without image guidance [46, 47]. All image acquisi-
tions for image-guided radiotherapy (IGRT) are performed
inside the treatment room (“in-room”), either on board of
the treatment device or integrated into the fixed treatment
room coordinate system to guarantee a stable geometric re-
lation between the imaging and treatment position. It has
to be ensured that the patient does not move due to the
change in treatment table position (e.g., between CT-on-
rails acquisition and treatment). If the target volume is not
visible on setup verification imaging, the geometric relation
between the target volume and its surrogates has to be ex-
tracted from primary treatment planning imaging and has to
be assumed constant between planning imaging and treat-
ment. If the relation cannot be assumed constant, additional
margins have to be applied.
Intracranial stereotactic radiosurgery and intracranial
fractionated stereotactic radiotherapy
Patient positioning and target volume localization for in-
tracranial stereotactic radiotherapy can be performed with
invasive rigid head frames using stereotactic localizers for
SRS [48–50] or with image guidance for both SRS and
FSRT [3, 9, 10]. FSRT with stereotactic frames requires
multiple invasive frame fixations and fraction-specific treat-
ment planning and should be avoided. Furthermore, target-
ing errors due to frame slippage of more than 2mm are
possible [51] and therefore image guidance should be per-
formed, if available. Image guidance can be performed us-
ing stereoscopic X-ray imaging [52, 53], in-room CT, or
on-board CT imaging [54–56]. Because of higher mobility
of the skull inside thermoplastic masks compared to inva-
sive frame immobilization [57], intrafraction head motion
monitoring and delivery adaptation in frameless SRS/FSRT
is required in order to minimize the planning target vol-
ume (PTV) margins [9, 42, 58]. Methods for intrafractional
motion monitoring can be found in section “Motion man-
agement”.
Extracranial stereotactic body radiotherapy
The intracranial image-guidance methods can be used for
extracranial target volumes as well [19–21, 25–27, 44, 59].
For additional information on surrounding critical struc-
tures, volumetric imaging is preferred over stereoscopic
imaging [60]. For some treatment sites, additional meth-
ods and techniques are available which can assist patient
positioning and target volume localization. However, those
methods are not yet able to replace the state-of-the-art X-ray
methods due to a lack of absolute target localization accu-
racy (e.g., ultrasound [61], surface scanning [62]) or a lack
of clinical data for stereotactic treatments (electromagnetic
tracking [63]). For targets moving with respiration or diges-
tion, patient positioning and motion management strategies
are discussed in the “Motion management” section below.
Discussion
There exist a large range of systems and methods for ac-
curate setup imaging for stereotactic radiotherapy in clini-
cal practice [48–63]. However, the question of which sur-
rogates are appropriate for targets that are not visible on
setup imaging [64–66] is beyond the scope of this review
and needs further investigation. As an example, implanted
fiducial markers may not always have a fixed inter- and in-
trafractional geometry with the actual target, and the num-
ber of fiducials (i.e., for rotation tracking), the geometric ar-
rangement, and the distance to the target strongly influence
treatment accuracy [67–70]. Additionally, special hybrid
treatment devices enabling MR image guidance for direct
localization of soft tissue targets [71] are emerging. Never-
theless, the current quality requirement as described above
explicitly excludes MRI-guided stereotactic treatments as
a standard, as this technique is considered to be under in-
vestigation with first available geometric and clinical data
for MR-guided SBRT [72–74], but without long-term fol-
low-up. Particularly for MR-guided intracranial treatments
is there currently a lack of clinical experience [75].
K
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Motionmanagement
Requirement: Systematic assessment and consistent con-
sideration of periodic and non-periodic target motion dur-
ing
 imaging for treatment planning;
 target volume definition;
 beam-delivery technique planning;
 dose simulation;
 target volume localization & repositioning; and
 dose application
using a time-resolved motion management strategy is re-
quired. Compensation of breathing-induced uncertainties
can be performed using breath-hold technique, free-breath-
ing with gated beam delivery, free-breathing with contin-
uous beam delivery using the internal target volume (ITV)
or mid-ventilation concept and free-breathing with dynamic
tumor tracking.
Intrafractional target motion describes any motion that
occurs during the delivery of a radiation therapy treatment
fraction and can be either periodic (breathing and/or heart-
beat induced, relevant for, e.g., lung and upper abdominal
lesions such as liver, pancreas, kidney, and adrenal glands)
[24, 76, 77] or non-periodic (mainly induced by sponta-
neous patient or target motion or from digestion, relevant
for, e.g., uveal, spine, intracranial, or prostate lesions) [43,
44, 57], which can induce systematic (e.g., baseline drifts)
or random treatment errors [3, 4, 19, 20, 24–26, 45, 46, 58,
68, 72, 78–81].
Any form of motion management tries to minimize the
relative motion between the target volume and the treat-
ment beam. Besides patient and/or target immobilization
and specific diet protocols to reduce non-periodic motion,
two general strategies to actively manage intrafractional tar-
get motion during dose application can be applied: tracking
and gating [3, 82–84]. All of these techniques require con-
tinuous or frequent position detection (motion monitoring)
of the target or a surrogate during dose delivery.
1. Tracking is defined as the pursuit of the target with the
beam, by automatically moving either the patient or
the beam corresponding to the motion-monitoring sig-
nal. Implemented clinical systems for beam tracking are
robotic-based [53] or gimbaled-based [85]. Under clin-
ical investigation are systems using multileaf collimator
(MLC) tracking [86, 87] or patient couch tracking [88].
There are three forms of tracking: free-breathing periodic
motion tracking (e.g., for lung and liver targets) [89, 90]
and non-periodic motion tracking (e.g., for intracranial,
spinal, and prostate targets), where the target volume
position is assumed to be constant between the updates
of the motion-monitoring signal [44, 89, 91] or for some
target volumes (e.g., in the pancreas) a combination of
both tracking techniques may be required [92].
2. Gating is defined as the triggering of the beam-on/off
status via a continuous motion-monitoring signal. The
beam is turned on if the signal is inside a gating win-
dow, defined during treatment imaging and planning, and
is turned off once the signal exits this gating window.
There are three forms of gating: free-breathing periodic
motion gating (e.g., based on a specific breathing phase
or amplitude for lung and liver targets [93–95]) and non-
periodic motion gating (e.g., based on breath-hold under
deep inspiration or expiration for lung and liver targets
[96, 97] or based on spontaneous motion in intracranial,
uveal, spinal, and prostate targets [98–100]) or a combi-
nation of both periodic and non-periodic motion gating
[72].
If no active motion management technique is available
for targets with non-periodic motion, additional safety mar-
gins should be considered. For targets with small periodic
motion (5mm), the internal target volume (ITV) or mid-
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ventilation (MidV) approach may be used instead of an ac-
tive motion management technique. For the treatment of
targets with larger periodic motion (>5mm), an ITV/MidV
approach is the minimum requirement if no active motion
management technique is available or feasible [3, 82]. The
ITV/MidV approach is a passive motion management tech-
nique that integrates time-resolved image information (in-
ternal motion) into the target volume by unifying all GTVs
(CTVs) from all breathing phase CTs to the ITV, or for
some cases by using a maximum intensity projection CT
dataset derived from the 4D-CT [101]. The MidV concept
uses the CT of the breathing phase nearest to the time-
weighted mean position of the GTV (CTV) and integrates
the peak-to-peak amplitude in all three directions into an
anisotropic PTV margin [102]. Thereby, the irradiated vol-
ume is enlarged such that the prescribed dose is sufficiently
delivered to the target during treatment, while the MidV
approach often leads to smaller irradiated volumes than the
ITV approach [102]. To reduce the irradiated volume, it can
be beneficial to reduce the motion amplitude, e.g., through
abdominal compression or active patient breathing training
[102]. The ITV/MidV approach performed under intrafrac-
tional verification of the target or surrogate motion can be
considered as gating with a full-amplitude gating window.
If for the ITV/MidV approach intrafractional verification of
the target or surrogate motion cannot be performed, addi-
tional uncertainty margins should be considered.
Regardless of the motion management strategy, the
coaching of breathing patterns (i.e., teaching the patient
how to breath) and the training of breathing (i.e., repeat-
ing the taught breathing patterns) prior to and the audible
and/or visual feedback of breathing during each of the
treatment steps for stereotactic radiotherapy can be cru-
cial to reduce treatment time, uncertainties, and errors [4,
103–106]. However, caution is strongly advised, as focused
breathing may also lead to increased tumor motion and
the feasibility and usefulness of coaching, training, and
feedback should always be evaluated on a case-by-case
basis.
The choice for one of these motion management strate-
gies defines the necessary requirements for all steps in the
treatment chain as described in the following.
Imaging for treatment planning
A free-breathing static CT of the lung and upper abdomen
suffers from motion artifacts like blurring of structures and
multiple representations of organ boundaries. It lacks valid
time-resolved information about target position, size, and
shape. To overcome these problems, respiration-correlated
4D-CT, prospectively gated multiphase CT, or a combina-
tion of inspiration and expiration breath-hold CT can be
acquired [82]. The reconstruction of 4D-CT data is most
frequently performed with a phase-based sorting algorithm
and up to 10 respiration phases. However, phase-based sort-
ing is more affected by breathing irregularity-related motion
artefacts compared to amplitude-based sorting [3, 20–22].
The use of time-resolved imaging allows for an assess-
ment of target motion and deformation as well as consis-
tency validation of the relationship between the target and
any surrogate used during dose delivery, regardless of the
motion management strategy. For targets with non-periodic
motion, a static CT should be used. Regardless of the target
location and the motion management strategy, special atten-
tion to patient preparation (e.g., positioning, organ filling,
and breathing pattern) has to be paid in order to reproduce
the internal situation of patient anatomy at the time of plan-
ning imaging during treatment.
Target volume definition
Uncertainties in target position and shape during treatment
have to be integrated into the target volume definition. Us-
ing an ITV/MidV approach, the target representation from
all available image data (e.g., from 4D CT) can be inte-
grated therein as described above, while the ITV needs an
additional PTV margin, which is included in the MidV ap-
proach. For all motion management techniques, the PTV
margin has to be enlarged such that all uncertainties from
motion representation in planning imaging and all uncer-
tainties related to the particular motion management strat-
egy during treatment previously not considered are covered
[89, 107]. Examples of motion management uncertainties
arise from uncompensated residual target motion, rotation,
and deformation [81, 108, 109], differential target and sur-
rogate motion (e.g., of target and implanted fiducials or di-
aphragm [66]), target–surrogate correlation modeling [80],
motion monitoring and correlation model update frequency
[110], and motion prediction modeling due to latency times
of the motion tracking systems [111, 112]. Typically for
stereotactic radiotherapy, PTV margins range from 0–2mm
for intracranial/spinal targets to 3–5mm for moving ex-
tracranial targets.
Beam-delivery technique planning
Beam technique factors (e.g., beam modulation, MLC leaf
travel) may be considered when treating moving targets.
Especially in some case scenarios with a low number of
fractions (e.g., 1–3) in combination with high dose rates
(e.g., when using flatting filter-free beams) such interplay
effects between target motion and moving parts of the de-
livery system could be significant and unpredictable [113,
114]. However, averaging effects for higher fractionated
stereotactic radiotherapy (e.g., 5or more) generally result in
a pure Gaussian blurring of the dose distribution that can be
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compensated by appropriate margins [115–117]. The sim-
plest method to prevent interplay effects can be realized by
avoiding modulated treatment sequences altogether.
Dose simulation
The dose delivery process is a time-dependent procedure,
but typically modeled as a static procedure with accord-
ing uncertainty margins in treatment planning. There are
several emerging approaches to overcome the differences
between static treatment planning and dose delivery un-
der target motion (e.g., 4D dose calculation [118–121], 4D
dose optimization [122, 123], and robust treatment planning
[124]). These techniques usually assume reproducibility of
the target motion at the time of imaging during treatment,
which has to be verified during treatment to evaluate the
reliability of the dose simulation.
Target volume localization & repositioning
For dose delivery, the assumptions made for target vol-
ume definition and treatment planning have to be fulfilled.
Therefore, the target volume itself has to be localized and
positioned before each fraction using the methods defined
in “Patient positioning and target volume localization”
above, adapted to the used motion management strategy.
Any in-room imaging for target volume localization has to
be accurately registered to the primary treatment planning
imaging data. For periodically moving targets, stereoscopic
X-ray imaging requires short acquisition times. Further-
more, breathing phase information for in-room imaging is
required (e.g., breath-hold position for on-board or sup-
plementary in-room imaging, or 4D-CBCT [59, 125]). An
exception to that is 3D-CBCT under free breathing. Here,
the 3D-CBCT can be used for ITV verification due to the
intrinsic averaging effects of the CBCT image acquisition
[126]. The target volume localization based on the meth-
ods as described has to be performed repeatedly during
treatment under consideration of the additionally applied
safety margin. If during repeated target volume localization
deviations from the treatment planning assumptions are de-
tected that are not covered by the additional safety margin
as described above, patient or beam repositioning or even
plan adaptation is required.
Dose delivery
For all motion management strategies, monitoring of tar-
get motion during treatment, taking into consideration the
applied safety margins, is required. Ideally, this may be
performed in real time and using non-ionizing volumetric
imaging [71, 127] (which is currently only available at a few
centers). For non-periodic target motion, deviations from
reference detected by continuous motion-monitoring sys-
tems may trigger renewed target volume localization and,
if necessary, patient repositioning [51, 52, 128]. If for pe-
riodic target motion continuous motion monitoring during
treatment is not feasible (e.g., due to target visibility or
imaging dose constraints), accurate correlation modeling
between the target and external surrogate signals (e.g., sur-
face or artificial marker [53, 62, 85, 129], spirometry [130],
etc.) or verification of the correlation model obtained dur-
ing planning imaging is strongly advised for stereotactic
radiotherapy. If the correlation model cannot be built or
verified (not recommended), larger additional uncertainty
margins must be considered. Correlation models have to be
repeatedly verified during treatment based on the fraction
duration and updated if necessary [131]. The motion man-
agement strategy must be adapted to the fraction duration,
which, in turn, should be kept as short as possible for most
applications (e.g., by using flattening filter-free beams with
high dose rates).
Discussion
A large variety of technologies and methods for periodic
and non-periodic motion compensation for all aspects of
the stereotactic radiotherapy treatment chain has been pre-
sented [82–132]. However, some of the techniques lack
standardized validation methods, mainly due to repeatabil-
ity during treatment (e.g., advanced 4D motion modeling
and 4D dose calculation or automatic registration of in-
trafractional images [6]). A similar related issue concerns
interfractional changes in patient anatomy and daily adap-
tive re-planning using newly available high-contrast volu-
metric imaging (e.g., MRI). Respective workflows are under
investigation and no general recommendations can be given
at the present time. Furthermore, we want to emphasize that
using an ITV/MidV concept for intrafractional breathing
motion compensation without verification and monitoring
of the actual target motion patterns before and during treat-
ment cannot be considered a best practice for stereotactic ra-
diotherapy of strongly moving targets. Several publications
reported significant changes in breathing patterns and ab-
solute target positions [133–135], which is particularly rel-
evant when treating in very few fractions (i.e., 1–3). Future
directions for motion management strategies for stereotactic
radiotherapy will comprise continuous volumetric imaging
during dose delivery [71, 72, 136] as well as online adap-
tation to possible changes in patient anatomy and motion
patterns of the target volume. In the end, only the assess-
ment of the in vivo tissue response will guide us towards
the needed technical and biological treatment accuracy for
stereotactic radiotherapy of moving targets [37].
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Collimation of the irradiation and beam directions
Requirement: For the respective treatment modalities, col-
limation and beam direction requires the following charac-
teristics:
 SRS with multileaf collimator (MLC) with leaf width
5mm or cylindrical collimators of equivalent size, both
at normal treatment distance, and used with systems
allowing non-coplanar beam directions.
 FSRT with MLC with leaf width 6.5mm or cylindrical
collimators of equivalent size, both at normal treatment
distance.
 SBRT with MLC with leaf width <10mm or cylindrical
collimators of equivalent size, both at normal treatment
distance.
However, for FSRT or SBRT close to radiation-sensitive
critical structures the same collimation and beam direction
requirements as for SRS are recommended.
Cylindrical collimators
The inherent precision of fixed circular collimators together
with their mount can be assumed to be in the range of
what is standard in mechanical engineering, that is, 0.1mm
and better. This translates into a high agreement between
the mechanical and radiological isocenter [137]. It is obvi-
ous that for small targets, a small collimator is needed to
achieve an adequate conformity of the dose distribution to
the target. Usually the lower limit of what is provided by
manufacturers today is 4–5mm. It should be noted that the
dose gradient is, in principle, steeper for smaller collima-
tor openings as can be shown for stereotactic convergent
beam irradiation [138]. However, for inverse-optimized flu-
ence-modulated delivery techniques, the effect of the single
collimator might be concealed. Based on their inherent me-
chanical precision, fixed collimators are generally suited for
SRS/FSRT and SBRT, at least if the collimator diameters
for the according treatment device allow for adaptation to
the actual tumor shape and size.
Multileaf collimators
Based on sampling theory, a lower MLC leaf width limit of
1.5 to 1.8mm (related to normal treatment distance), below
which the dose distribution cannot be refined further, can be
assumed for radiotherapy [139]. However, the vast majority
of MLCs presently used for stereotactic radiotherapy have
leaves that are much wider.
One planning study compared MLC leaf widths of
2.5mm and 5mm using both step-and-shoot intensity-mod-
ulated radiation therapy (IMRT) and intensity-modulated
arc therapy (IMAT) techniques on two different phantoms
mimicking small- and large-field head and neck targets
[140]. The study found that for small fields and a small
c-shaped target around an organ at risk (OAR), improved
conformity for the 2.5mm MLC was observed with a lower
maximum for the OAR together with lower peripheral
doses. This advantage was more pronounced for IMAT. In
contrast, for so-called normal sized head and neck targets,
the study did not find dosimetric benefits by using the
2.5mm instead of the 5mm MLC. Additionally, a study
comparing a 3mm MLC leaf width with a 5mm MLC
found that equivalent coverage with both MLCs can be
achieved, whereas there was a statistically significant better
conformity for the 3mm MLC [141]. However, with both
MLCs, the clinical predefined dose criteria (e.g., RTOG
dose limits) could be fulfilled for all cases.
In another planning study on IMRT for prostate targets,
the influence of the leaf width using three different MLCs
with 2.5, 5, and 10mm leaf width was investigated [142].
The study found significant improvements in dose cover-
age for the 2.5 and 5mm MLCs in relation to the 10mm
leaf width, but no significant gain when reducing the leaf
width from 5 to 2.5mm. Similar to this, a study compar-
ing three different MLCs with leaf widths of 2.5, 4, and
5mm for IMAT of spinal targets with volumes between 24
and 220cm3 concluded that any of these leaf widths can be
used for spinal SBRT [143]. Furthermore, a study on the
difference between planning with an MLC leaf width of
2.5 vs. 5mm with respect to different levels of plan com-
plexity, namely 5- up to 17-field IMRT and IMAT with
one or two arcs for the treatment of pituitary adenomas,
demonstrated coverage and conformity improvement with
the smaller leaves of about 2% for the 5-field IMRT and
only about 0.5% for the two-arc IMAT technique [144].
These studies might be exemplary to show that there
is a notable benefit in reducing the MLC leaf width from
10mm, but the benefit of using leaves smaller than 5mm
seems only marginal, maybe except for small or very ir-
regularly formed targets. However, the differences between
treatment platforms can be compensated when using more
complex delivery techniques (e.g., [144, 145]), besides
other influences on the comparison, such as calculation
grid size. Part of this ambiguity is likely caused by the fact
that MLC leaf width on the one hand is an easily defined
quantity, but on the other hand, the mechanical size of the
leaves is only one parameter among many in defining the
actual geometrical resolution for an MLC.
According to sampling theory, the 20–80% beam penum-
bra divided by 1.7 equals the optimal sampling distance,
which can be half the size of the leaf width (achievable,
e.g., by a couch displacement of half the leaf width) [139].
Hence, the beam penumbra is crucial for the geometrical
resolution of an MLC and the penumbra is mainly defined
by the construction of the collimator head. Manufacturers
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place the MLC at different positions with respect to the di-
aphragm(s) and, by the same token, to the patient, which
can lead to variations in the penumbra by a factor of about
1.5 ([146], the principal differences between manufactur-
ers of newer MLCs are similar). In addition, ideas exist
to reduce the leaf resolution and penumbra for the given
mechanical setups, e.g., by using a so-called virtual isocen-
ter, which adds to the complexity of defining the treatment
quality solely based on the MLC leaf width [147]. Another
example of a factor influencing the beam penumbra is the
elongated elliptical shape of the beam focus with a relation
of 1 to 2 for the axes using an achromatic 270° bending
magnet system [148]. From that, a dependence of the beam
penumbra on the diaphragm angle would follow.
The importance of the beam focus size as a crucial beam
parameter is widely stressed in connection with small field
dosimetry (e.g., [3]). However, measurement or simulations
are cumbersome and, to our knowledge, are nowhere in-
cluded in routine quality assurance or beam commission-
ing. This leads to the question of how these parameters are
correctly implemented into the treatment planning system
Hier steht eine Anzeige.
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at all, since in many cases the baseline data, e.g., beam
profiles, consist only of measurements of the fixed jaws.
These considerations illustrate that a certain leaf width
alone as a requirement to define treatment quality might not
be meaningful. However, for a simple definition based on
the literature, we can determine that an MLC leaf width of
below 10mm is mandatory for stereotactic radiotherapy and
that a leaf width of about 5mm or less is recommended.
Helical and coplanar-only radiotherapy
Helical radiotherapy requires special consideration, as the
MLC leaf width might be larger compared to the gantry-
based MLC systems used for SRS and FSRT (i.e., 6.25mm)
but the delivery technique is different (helical) and it is
in fact claimed to be used clinically for SRS and FSRT
(e.g., [149–154]). However, in connection with helical treat-
ment, especially for SRS, the inherent coplanarity of this
modality (and for others, too) might be an additional disad-
vantage [155–157]. When compared with other stereotactic
radiotherapy treatment platforms, helical radiotherapy per-
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formed worse in some of the studies [158, 159], though
not in all cases. In a planning study comparing forward-
planned stereotactic conformal radiation therapy (SCRT),
IMRT, and helical radiotherapy, the results demonstrated
that helical radiotherapy was superior to SCRT, including
a better hippocampal sparing for close target lesions [159].
Additionally, another study claimed that sparing the hip-
pocampus was feasible with four treatment platforms, in-
cluding one for helical radiotherapy [160]. Furthermore, in
one study, helical radiotherapy was even favored over cone-
based gantry-based linear accelerators in cases where OAR
prevented the use of non-coplanar beams [158]. Likewise,
another study could not show superiority (or inferiority) of
helical radiotherapy over gantry-based systems for arteri-
ovenous malformations in general, but found advantages
for the former for targets with special geometry [161].
From a more theoretical point of view, one could ap-
ply the argument of the sampling theory regarding optimal
leaf resolution especially to helical radiotherapy, because
it is rather sampling and not leaf width which defines the
resolution of an MLC [139]. The continuous couch move-
ment, inherent to helical treatment, produces a sample width
which is smaller than the field width parallel to the couch
motion direction (minimal 1cm) and the perpendicular leaf
width itself, and thus should produce a better resolution
than could be expected from mechanical size alone. In
conclusion, there seems to be sufficient physical rationale
to not exclude helical therapy from being used for FSRT.
However, for very small targets and situations where non-
coplanar beams might be of advantage, the use of helical
radiotherapy is not advised [155–157].
Discussion
We found that the MLC leaf width may be a simple mea-
sure for assessment of the geometrical resolution of treat-
ment platforms and hence serve as a quality requirement for
stereotactic radiotherapy based on the literature [139–148].
However, looking deeper into the treatment plan quality,
the MLC leaf width does not directly represent the mini-
mal possible field size, which is, together with the beam
penumbra and its origins (e.g., beam spot size), also an
important parameter to define the geometrical resolution
[162]. These influences should be further investigated, es-
pecially when looking at SRS and FSRT using very small
MLC or circular collimator fields with inherent dosimetric
inaccuracies, e.g., due to shielding of the primary source
with the collimator. For very small fields formed by a dy-
namic aperture (MLC or, e.g., CyberKnife IRIS collimator
[Accuray Inc, Sunnyvale, USA]), the accuracy and repro-
ducibility of leaf (or aperture) positioning should also be
considered in an analysis of dosimetric reliability. Another
aspect of treatment plan quality is the simple fact that the
hardware alone does not make a good treatment plan, which
is always a combination of conformity to the target volume,
steep dose gradients in the healthy tissue, and the technical
applicability under realistic conditions. Treatment planning
techniques (e.g., coplanar vs. non-coplanar techniques in-
cluding table angle selection [157] and number of fields
or beam energy) are strongly method dependent and sig-
nificantly influence the treatment plan quality [155, 156,
163–166]. While this has been investigated for numerous
indications and well-described methods exist to improve
treatment planning [167], center or even user credentialing
for stereotactic radiotherapy is still lacking in Germany.
Dose calculation
Requirement: For stereotactic radiotherapy in areas with
large density inhomogeneities the use of a dose calculation
algorithm that takes into account lateral electron transport
to correct for density inhomogeneities is required. The max-
imum grid size for dose calculation should be 1–2mm ac-
cording to the target lesion dimensions and the image reso-
lution for target definition.
Primarily, the dose calculation for stereotactic radiother-
apy applications is performed on the primary treatment
planning CT and the accuracy of a dose calculation algo-
rithm is strongly influenced by the underlying physics mod-
elling the transport of secondary particles (i.e., scattered
photons and electrons). While this problem is less relevant
for homogeneous situations and field sizes larger than about
3× 3cm2 (or associated to the range of electrons), it is cru-
cial in areas with high density differences (e.g., in thoracic
or head and neck regions) and for small field sizes espe-
cially when combined with high-energy treatment beams.
The range of suitable beam energies is considered to be
10MV due to the reduced range of secondary electrons,
the reduced transmission through the beam defining system,
and the reduced neutron production when compared with
beam energies larger than 10 MV [3]. It is important to
understand that it is mainly the management of the lateral
spread of scattered particles that determines the accuracy
level of a dose calculation algorithm. This is the back-
ground to distinguish between type-A algorithms, which
model only the primary particle transport correctly and in
which the approximation of the secondary particle trans-
port is generally based on equivalent path length scaling,
and type-B algorithms, which include more sophisticated
models for the management of secondary particles [3]. Ex-
amples of type-A algorithms are ray-trace algorithms, pen-
cil beam algorithms, or fast Fourier convolution algorithms,
which all ignore changes in lateral electron transport. Con-
volution/superposition algorithms as well as collapsed cone
convolution algorithms, which take changes in lateral elec-
tron transport into account, are examples of type-B algo-
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rithms. The anisotropic analytical algorithm (AAA) is con-
sidered an intermediate type-A/type-B algorithm. The more
advanced type-B algorithms sometimes also referred to as
type-C algorithms, which explicitly consider the lateral par-
ticle transport, include Monte Carlo algorithms as well as
solver of the Boltzmann transport equation [3, 168].
For radiotherapy applications using photon beams in-
cluding stereotactic techniques, the dose calculation algo-
rithm determines the absorbed dose within a volumetric
element (dose scoring voxel) of a given CT dataset repre-
senting the patient’s characteristics. The resulting accuracy
of the estimated dose distributions for the different dose
calculation algorithm depends on the specific situation con-
sidered such as field size, photon beam energy, dose scoring
voxel size, and tissue/density heterogeneity (i.e., treatment
site specific), but also on the implementation of the algo-
rithm itself. In addition, the accuracy depends on the accu-
racy of the beam model used by the dose calculation algo-
rithm along with a careful commissioning and validation,
especially with the focus of the foreseen clinical applica-
tion [3]. This may include additional tasks like verification
of output factors for very small field sizes and the con-
sideration of appropriate dose calculation algorithm quality
assurance procedures following updates or upgrades. Fur-
thermore, it is important to understand not only the approx-
imations used in the dose calculation model, but also its
implementation in order to anticipate potential shortcom-
ings for dedicated applications (e.g., high resolution of the
fluence is more important for small than for large radiation
fields).
Typically, the accuracy for small field sizes and large
energies is reduced in tissues with densities substantially
different from water (e.g., lung [169, 170]). In terms of
dose scoring improved accuracy is reported, when smaller
voxel dimensions are used [171]. For stereotactic applica-
tions, an isotropic grid size of smaller than or equal to 2mm
is considered appropriate [2]; however, for very small tar-
gets, dose grid resolution of 1mm or better may be needed
[172]. Regardless of the dose grid resolution and the dose
calculation algorithms used, the resolution of the primary
planning imaging on which the dose calculation is per-
formed should always be equal to or better than the dose
grid resolution. Many studies have been performed to in-
vestigate the level of accuracy for different dose calculation
algorithms involving small field sizes and tissue inhomo-
geneities: in summary, type-A dose calculation algorithms
lead to dose overestimation in target volumes located in
low-density tissue when compared with type-B algorithms
or with detailed measurements [3, 173]. The approxima-
tions used in these algorithms lead to inaccurate dose dis-
tributions when low-density tissue is involved and thus are
not appropriate for stereotactic treatment planning. Studies
showed that intermediate type-A/type-B algorithms, i.e., in-
cluding the AAA algorithm, provided acceptable estimation
of dose distributions for stereotactic applications if no low-
density tissue is present, but they are of limited accuracy
in the context of lung SBRT [168, 174–177]. Investigations
of the performance of type-B algorithms demonstrate the
suitability of these algorithms for stereotactic radiotherapy
purposes [2, 173, 178, 179]. Finally, studies showed that
advanced type-B (or type-C) algorithms accurately calcu-
late dose for small fields in heterogeneous tissue and are
best suited for stereotactic radiotherapy treatment planning,
as recommended by the International Commission on Ra-
diation Units and Measurements (ICRU) report 91 [3].
Discussion
It is largely agreed upon that dose calculation should be as
accurate as clinically feasible and density inhomogeneities
can be addressed with modern dose calculation algorithms
[2, 168–179]. However, another aspect is the influence of
the dose calculation algorithm on the actual prescription
(e.g., based on different dose calculation or PTV coverage
based vs. GTV mean dose based [3]) in clinical protocols.
Given the experience gathered for a specific protocol, it is
not trivial to transfer such a protocol and clinical experience
to another, typically more advanced, dose calculation algo-
rithm, since in general the difference in the estimated dose
distribution due to different dose calculation algorithms is
not a simple scaling factor [180–182]. Additionally, no con-
sensus has currently been reached for the actual primary
planning CT for dose calculation for targets with period
motion (e.g., mean-intensity-projection, specific breathing
phase with or without density overwrite, etc.) [3]. Hence,
harmonization in dose prescription based on similar accu-
rate dose calculation algorithms is still largely lacking. Fur-
thermore, not only the target volume has to be considered,
but the differences that might occur in organs at risk are
also important [183, 184].
Furthermore, MRI is often used due to the high soft tis-
sue contrast and the MR images are then registered to the
CT dataset in treatment planning [185]. In order to over-
come image registration errors, the use of MR-only treat-
ment planning is of increasing interest [186]. While MR-
only planning is common practice for Gamma Knife treat-
ments, a synthetic CT is typically generated based on the
MR image dataset when using other treatment modalities.
However, there are currently still limitations in the MR-only
approach for stereotactic radiotherapy, which comprise dose
calculation uncertainties due to errors in HU assignments
and image distortions [186]. Currently, there is no consen-
sus whether these errors counterbalance the benefits of an
MR-only planning approach. Additionally, beam delivery
under MR real-time guidance may necessitate incorporat-
ing the MRI-based dose distortions into dose calculation,
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especially in areas with density inhomogeneities. Thus, ad-
ditional studies have to be performed on this topic.
Treatment unit accuracy
Requirement: A geometric accuracy with three-dimen-
sional spatial dose placement in system-specific end-to-
end tests requires inaccuracies of at maximum:
 1mm for SRS.
 1.25mm for FSRT and SBRT in non-moving phantoms.
 1.5mm for SBRT in moving phantoms.
However, for FSRT and SBRT close to radiation-sensitive
critical structures the same geometric accuracy requirement
as for SRS is recommended.
A dosimetric accuracy with point-based plan-to-mea-
surement differences of maximum 3% within a target vol-
ume of more than or equal to 2cc, measured in system-
specific end-to-end or delivery-quality-assurance tests with
homogeneous phantoms, is required. For target volumes
smaller than 2cc, the uncertainties of the measurement may
be larger than the desired dosimetric accuracy.
The dedicated distributed literature search in PubMed/
Medline revealed a total of 462 publications for the key-
words used. After conference abstracts removal and head-
line screening by experts in the field, a total of 53 pub-
lications remained for further screening. Due to the na-
ture of a distributed literature search, the results were then
combined and the duplicates were removed. After final ab-
stract screening and after adding well-known guidelines
for stereotactic radiotherapy not listed in PubMed/Medline,
a total of 35 publications and guidelines remained for full
data extraction. The complete data extracted for the pub-
lications and guidelines can be found in Table 1 in the
supplementary material (Online Resource 1).
Concerning international guidelines, the IAEA technical
report series 483 advised a geometric accuracy of 2mm and
a dosimetric accuracy of 3–10% in system-specific end-to-
end tests [154]; however, this advice is for radiotherapy in
general and not specifically tailored to stereotactic radio-
therapy. The ESTRO/ACROP guideline for lung SBRT on
the other hand advised a geometric and dosimetric accuracy
of 0.5–4mm (median 1.25mm) and 2–5% (median 3%), re-
spectively [20]. Other notable international guidelines, in-
cluding the AAPM-RSS Guideline 9a for SRS-SBRT, rec-
ommended a geometric accuracy of 1mm for static and
1.5mm for moving targets with 5% dosimetry accuracy
[172]. This is in line with previously published system-spe-
cific AAPM TG reports [187]. On the other hand, the recent
COMP reports for the same system advised on a geometric
accuracy of 0.75mm for static and 1.0mm for moving tar-
gets based on recent developments in the system’s architec-
ture [188]. Interestingly, no guideline reported specifically
on the overall phantom test uncertainty, but of course the
phantom test uncertainty itself plays an important role in
the measured overall accuracy of the stereotactic treatment
system as well. One example is the lack of recommenda-
tions on the necessary slice thickness for the phantom CT
scan used for the end-to-end tests and we strongly recom-
mend achieving the highest possible resolution, at least not
worse than the resolution used for patient scans.
Furthermore, there are numerous guidelines which only
present overviews of the published literature without giving
clear recommendations, including the ICRU report 91 [3]
and the AAPM TG 101 report [2]. The geometric accuracy
in these reports ranges from 0.28± 0.36mm to 1.5± 0.7mm
depending on system, test scenario, and measurement de-
vice. Adding recent literature to these guidelines, one can
safely assume on one hand that well-calibrated dedicated
stereotactic radiotherapy equipment can reach the required
level of mechanical precision of 1mm in system-specific
static end-to-end tests for SRS [189–197]. Additionally,
a geometric accuracy of 1mm is clearly necessary for
SRS in order to keep the overall PTV margin 2mm when
also considering patient motion during treatment before side
effects increase significantly for the high SRS doses [9]. At
this point, it should be noted that a PTV margin of 0mm,
which is often used in SRS, is geometrically infeasible with
the current treatment units under consideration of patient
and target motion. Hence, the use of a 0mm PTV margin
may be derived from clinical decisions and potentially be
compensated by higher prescription doses.
When looking at non-continuous volumetric imaging
alone (i.e., CBCT), there are a number of reports of end-
to-end tests exceeding the limits of 1mm [3, 198–201],
even though the recent COMP report on CBCT advised
achieving a geometric accuracy of <1mm [201]. Hence,
the accuracy of CBCT alone may not necessarily be suffi-
cient for SRS, especially when further considering patient
motion during treatment (see the “Patient positioning and
target volume localization” and “Motion management”
sections above). On the other hand, for FSRT and SBRT
in non-moving organs, the required geometric precision of
1.25mm should be achievable with well-calibrated CBCT
systems, which then may be sufficient to keep the overall
treatment accuracy below 2–3mm when considering pa-
tient motion during treatment [9]. This recommendation
is also in line with guidelines and studies including he-
lical therapy and recently introduced integrated MR-linac
devices [3, 189, 190, 202, 203]. However, when looking
at irregular moving targets for SBRT, the geometric ac-
curacy of any system in current clinical use may quickly
exceed the required limits of 1.5mm in moving phantoms
[172, 187, 204], and only careful motion modeling and
compensation may allow the overall PTV margins to be
kept below 3–5mm when additionally considering patient
K
motion and local target baseline shifts and deformation
during treatment (see “Motion management” section).
Concerning the dosimetric accuracy of the treatment sys-
tems used for stereotactic radiotherapy, high-quality data
arise mostly from clinical trial audits. In homogeneous
phantoms, the dosimetric end-to-end or delivery-quality-as-
surance accuracy was found to be well below the required
3% limit [190, 197, 205–207]. However, when looking at
moving targets and especially those targets surrounded by
heterogeneous tissue, it becomes apparent that the 3% dosi-
metric accuracy cannot always be reached without type-C
dose calculation algorithms (see “Dose calculation” sec-
tion) [205].
Discussion
All dedicated and well-tuned devices for stereotactic ra-
diotherapy can fulfill the obligations for high geometric
and dosimetric accuracy during end-to-end tests [2, 3, 9,
89, 172, 187–219]. However, when target motion comes
into consideration, the acceptable limits may quickly be
exceeded for certain scenarios. Furthermore, clear recom-
mendations for the acceptance of end-to-end tests for mov-
ing targets in heterogeneous tissues are currently lacking.
Furthermore, no data exist to support a recommendation
on any system-specific end-to-end or delivery-quality-as-
surance test for small target volumes (i.e., 2cc). Due to
current measurement uncertainties for very small radiation
fields, we cannot recommend any valid approach or solid
reference at this time [148, 220]. This should be further
explored. Additionaly, no clear recommendations on the
method and the acceptance criteria of delivery-quality-as-
surance tests can be given, since the literature including in-
ternational recommendations is largely heterogeneous and
even contradictory to some degree.
Dedicated quality assurancemeasures
Requirement: Dedicated quality assurance measures are
required:
 Small field dosimetry for commissioning.
 System specific end-to-end testing for both static and
moving target volumes.
 Regular check of the geometric and dosimetric accuracy
according to system-specific guidelines.
 Day-to-day quality control of the consistency of the
stereotactic frame and/or the image-guidance system
isocenter with the treatment beam isocenter.
Stereotactic radiotherapy makes use of small radiation
fields due to the generally small targets treated [3]. Hence,
it becomes necessary to use adequate measurement tools
and compensate for measurement uncertainties in small
Hier steht eine Anzeige.
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fields specifically during system commissioning (e.g., us-
ing correction methods for output factor measurements for
the smallest field sizes), but also for the whole quality as-
surance chain. For small field dosimetry, the IAEA has re-
cently reported a comprehensive practical guideline [208]
and the German Institute for Standardization (Deutsches
Institut für Normung [DIN]) has published a new norm for
the dosimetry of small photon beams [220], both which we
consider mandatory state-of-the-art practice for stereotactic
radiotherapy.
Further, for full commissioning of radiotherapy devices
used for stereotactic radiotherapy, dedicated full treatment
chain end-to-end tests are required [221]. In this regard,
a full treatment chain end-to-end test phantom validation
must include all treatment steps including primary and sec-
ondary imaging and its registration and subsequent tar-
get volume delineation (“Imaging for target volume def-
inition”), dose calculation (“Dose calculation”), phantom
positioning and target volume localization (“Patient posi-
tioning and target volume localization”), and target motion
compensation (“Motion management”), and must fulfill the
specified geometric and dosimetric accuracy (“Treatment
unit accuracy”). Therefore, system-specific end-to-end tests
both for static (i.e., cranial) and for moving (ideally for both
periodically, e.g., lung and liver, and non-periodically mov-
ing, e.g. prostate) target volumes are required.
Once the stereotactic radiotherapy device is fully com-
missioned, regular checks of the geometric and dosimet-
ric accuracy have to be performed in order to ensure the
system’s integrity and to find system drifts and inaccura-
cies early before clinical consequences can arise. There are
a wide range of system specific recommendations avail-
able which are considered mandatory state-of-the-art prac-
tice for each of the systems in description [172, 187, 188,
201, 209, 221, 222]. Parts of these recommendations are
specific details on daily quality assurance which minimally
requires verification of the consistency of the stereotactic
frame and/or the image-guidance system with the treatment
isocenter (which is a modern version of the so called Win-
ston–Lutz test [223], normally reduced in number of in-
spected axes for a daily check).
Discussion
Recently, comprehensive small-field dosimetry and system-
specific quality assurance guidelines have been published
for stereotactic radiotherapy [172, 187, 188, 201, 208, 209,
220–222]. However, the translation from the old to the
new methods has only just begun and the clinical impli-
cations are not yet fully understood (e.g., when correct-
ing the output factors and hence changing the absolute
dose for high-dose small-field SRS for trigeminal neural-
gia). Another point is that contouring based on MRI as
well as treatment planning are generally not part of the
end-to-end test chain, though they clearly should be. Fur-
thermore, generally only the simplest forms of end-to-end
tests are performed, leaving many treatment scenarios un-
verified (e.g., non-isocentric and/or simultaneous multiple
lesion treatment techniques and complex moving and/or de-
forming target volumes with dual periodic, i.e., respiratory
and cardiac motion, and/or non-periodic motion). However,
current phantoms in routine clinical practice may not even
allow for such scenarios to be simulated. Additionally, the
interval for repeating full treatment chain end-to-end and
delivery-quality-assurance tests is not well agreed upon.
Regardless, independent validation methods and external
audits are also lacking specifically for stereotactic radio-
therapy in Germany.
Conclusion
The present expert review from the DGMP Working Group
for Physics and Technology in Stereotactic Radiotherapy
summarizes technological quality requirements for stereo-
tactic treatments using photon external beam radiotherapy
in the form of necessary minimum requirements often com-
plemented by recommendations or suggestions for optimal
quality. Additionally, open questions in each of the seven
sections are identified. “Imaging for target volume defini-
tion” emphasizes the need for indication-adapted treatment
planning imaging, gives information on the use of multiple
secondary imaging datasets for many treatment sites, and
complements this with statements on reliable image regis-
tration with the planning CT.
In “Treatment unit accuracy” the requirements for inter-
fractional patient positioning and target volume localization
based on daily IGRT depending on technique (SRS, FSRT,
SBRT) and visibility and anatomic properties of the target
volume and nearby critical structures are described. These
requirements are extended to further methods supporting
intrafractional target volume localization as illustrated in
“Motion management.” Here, the whole treatment chain
from treatment planning imaging to dose delivery and their
specific requirements for consistent motion management is
described. Thereby, the choice of the motion management
technique is considered the most important first step, as the
technique will have strong impact on each individual link
in the treatment chain.
“Collimation of the irradiation and beam directions”
summarizes the requirements on beam collimation and
beam directions, with a detailed analysis of the influence
of MLC leaf width and other hardware components on
the treatment plan quality. Adding to that, in “Dose cal-
culation,” the necessity of a dose calculation algorithm
suited to the tissue density properties in the target region is
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emphasized and explained. This necessity is extended by
a description of the influence of the dose grid resolution
and beam energy on the dose calculation accuracy.
The requirements of the geometric and dosimetric treat-
ment unit accuracy with static and moving homogeneous
phantoms are given and discussed in “Treatment unit accu-
racy.” This section is supported by a detailed supplemen-
tary table containing published recommendations and data
for various treatment systems. Lastly, “Dedicated quality
assurance measures” describes the necessary quality assur-
ance procedures to guarantee the needed technological qual-
ity requirements from commissioning to end-to-end testing
for static and moving targets up to required daily quality
checks.
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